Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT + Atezolizumab + Bevacizumab in Unresectable HCC Progressors
NCT07276100Phase 2Recruiting
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in hepatocellular carcinoma (HCC), sponsored by Sant'Orsola-Malpighi University Hospital. Started Jan 2026; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07276100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276100.